2-Adrenergic Agonists in the Treatment of Children with Asthma
1 4540 Sand Point Way NE, Seattle, Washington 98105
2 344 Kearny Villar Road, San Diego, California 92123
3 Department of Pediatrics and Child Health, University of Manitoba Children's Hospital of Winnipeg Winnipeg, Manitoba R3A 1S1 Canada
4 6667 Vernon Woods Drive Atlanta, Georgia 30328-3279
-Adrenergic agonist therapy was associated with increased asthma mortality when high-potency isoproterenol was used in the United Kingdom in the 1960s, and when the
-agonist fenoterol was used increasingly in New Zealand in the 1970s.1-3 Recently, a Canadian epidemiologic study reported an increased risk of death with regular use of
-agonists, particularly fenoterol.4 Fenoterol may be uniquely less safe than other
-agonists because of a greater cardiotoxic potential due to less
2 specificity (than terbutaline) and a greater relative dose per actuation.5 The concerns about the safety of
-agonists are linked intimately with the concerns about their effectiveness in asthma therapy.